Header Logo

Connection

Ian Dunn to B7-H1 Antigen

This is a "connection" page, showing publications Ian Dunn has written about B7-H1 Antigen.
Connection Strength

1.960
  1. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary. 2021 Jun; 24(3):359-373.
    View in: PubMed
    Score: 0.725
  2. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22; 7(47):76565-76576.
    View in: PubMed
    Score: 0.543
  3. Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status. J Neurooncol. 2021 Feb; 151(3):443-449.
    View in: PubMed
    Score: 0.182
  4. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Sci Rep. 2020 06 03; 10(1):9027.
    View in: PubMed
    Score: 0.173
  5. Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res. 2020 03 01; 26(5):1141-1151.
    View in: PubMed
    Score: 0.167
  6. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16.
    View in: PubMed
    Score: 0.121
  7. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.